Embodiments of the subject matter described herein relate generally to medical devices, and more particularly, embodiments of the subject matter relate to the identification of fluids for delivery from infusion devices.
Infusion pump devices and systems are relatively well known in the medical arts, for use in delivering or dispensing a fluid agent or infusate, such as insulin or another prescribed medication, to a patient. A typical infusion pump includes a pump drive system which typically includes a small motor and drive train components that convert rotational motor motion to a translational displacement of a plunger (or stopper) in a reservoir that delivers medication from the reservoir to the body of a user via a fluid path created between the reservoir and the body of a user. Use of infusion pump therapy has been increasing, especially for delivering insulin for diabetics.
In practice, it is desirable to facilitate preparation of infusate for delivery to a patient or user. Specifically, there is a desire to reduce errors when preparing the infusate for delivery. Typically, a user must transfer the infusate from a vial to a device reservoir and then couple the device reservoir to a fluid delivery device. Different concentrations of infusates are increasingly common commercially. However, accidental use of a higher concentration than intended may cause severe injury or death to the patient.
Accordingly, there is a need to accurately identify the infusate in the reservoir before delivery from infusion devices. Further, there is a need to provide an automated apparatus, system and method for examining a fluid in the reservoir of an infusion device that satisfies the various requirements that may be imposed.
Apparatuses and methods for identifying an infusate in a reservoir of an infusion device and systems for use in filling fluid delivery devices are provided. An exemplary apparatus for identifying an infusate in a reservoir of an infusion device includes a chamber in selective fluid communication with the reservoir. Further, the apparatus includes an indicator located in the chamber. The indicator exhibits a visual change when contacted by a selected infusate. The apparatus also includes a detector arrangement to identify the infusate by detecting the visual change in the indicator. An exemplary detector arrangement may include a camera to capture an image of the infusate and indicator in the chamber, and an identifier element to compare image data to a library of stored image data.
In another embodiment, a system for use in filling a fluid delivery device includes a reservoir to hold a fluid and adapted for connection to the fluid delivery device. The system further includes a one-way valve interconnecting the reservoir and a chamber. The one-way valve selectively allows fluid flow from the reservoir to the chamber. Also, the system includes a camera to capture an image of the fluid in the chamber and to generate a signal including image data. Further, the system includes an identifier element in electronic communication with the camera to analyze the signal to identify the fluid.
Another embodiment provides a method for identifying an infusate in a reservoir of an infusion device. The method includes filling the reservoir with the infusate. A portion of the infusate flows through a one-way valve into a chamber and contacts an indicator located in the chamber. The indicator exhibits a visual change when contacted by the infusate. The method includes capturing an image of the infusate and indicator in the chamber. Also, the method includes generating a signal including data associated with the image. Further, the method includes analyzing the signal to identify the infusate.
This summary is provided to introduce a selection of concepts in a simplified form that are further described below in the detailed description. This summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used as an aid in determining the scope of the claimed subject matter.
A more complete understanding of the subject matter may be derived by referring to the detailed description and claims when considered in conjunction with the following figures, wherein like reference numbers refer to similar elements throughout the figures, which may be illustrated for simplicity and clarity and are not necessarily drawn to scale.
The following detailed description is merely illustrative in nature and is not intended to limit the embodiments of the subject matter or the application and uses of such embodiments. As used herein, the word “exemplary” means “serving as an example, instance, or illustration.” Any implementation described herein as exemplary is not necessarily to be construed as preferred or advantageous over other implementations. Furthermore, there is no intention to be bound by any expressed or implied theory presented in the preceding technical field, background, brief summary or the following detailed description.
While the subject matter described herein can be implemented in any electronic device, exemplary embodiments described below are implemented in the form of medical devices, such as portable electronic medical devices. Although many different applications are possible, the following description focuses on a fluid infusion device (or infusion pump) as part of an infusion system deployment. For the sake of brevity, conventional techniques related to infusion system operation, insulin pump and/or infusion set operation, and other functional aspects of the systems (and the individual operating components of the systems) may not be described in detail here. Examples of infusion pumps may be of the type described in, but not limited to, U.S. Pat. Nos. 4,562,751; 4,685,903; 5,080,653; 5,505,709; 5,097,122; 6,485,465; 6,554,798; 6,558,320; 6,558,351; 6,641,533; 6,659,980; 6,752,787; 6,817,990; 6,932,584; and 7,621,893; each of which are herein incorporated by reference.
Embodiments of the subject matter described herein generally relate to infusion systems including a fluid infusion device having an apparatus for identifying the infusate or infusion media that is prepared for delivery to the user or patient. Embodiments provide for automated examination of the infusate to ensure that the proper infusate and the proper concentration of the infusate are coupled to the fluid infusion device. Exemplary embodiments utilize an indicator that exhibits a visual change when contacted by a selected infusate. For example, the indicator may change color and may cause a portion of the infusate to change color. The resulting color is indicative of a specific infusate and concentration of the infusate. For example, a concentration of U-100, U-200, U-300, and U-500 insulins react differently to the indicator and form differently colored solutions.
In exemplary embodiments, a portion of the infusate is selectively separated from the reservoir and is contacted with the indicator. For example, a one-way valve may be utilized to transfer a portion of the infusate from the reservoir to a testing chamber. The one-way valve prevents flow of the indicator or of infusate mixed with the indicator from the testing chamber into the reservoir.
Exemplary embodiments further include an image capture device, such as a camera, for recording the color of the indicator and the portion of the infusate in the chamber. A signal including image data is then analyzed, such as by comparison with image data from previously tested infusates, to determine the identity of the infusate received in the reservoir.
The disclosure relates generally to delivery devices, systems and methods for delivering infusate or infusion media, such as a drug, to a recipient, such as a medical patient. In particular embodiments, a delivery device includes a disposable portion that secures to the recipient and that may be readily disposed of after it has been in use for a period of time. Such embodiments may be configured to provide a reliable, user-friendly mechanism to secure the delivery device to a patient for delivery of fluidic infusion media to the patient. Embodiments may be configured with feature that enhance the ease by which patients may secure the delivery device to the patient's skin and further features that enhance the ease by which patients may fill, re-fill or replace spent infusion media.
While embodiments are described herein with reference to an insulin delivery example for treating diabetes, other embodiments may be employed for delivering other infusion media to a patient for other purposes. For example, further embodiments may be employed for delivering other types of drugs to treat diseases or medical conditions other than diabetes, including, but not limited to drugs for treating pain or certain types of cancers, pulmonary disorders or HIV. Thus, the infusate may be insulin, HIV drugs, drugs to treat pulmonary hypertension, iron chelation drugs, pain medications, anti-cancer treatments, medications, vitamins, hormones, or the like. Further embodiments may be employed for delivering media other than drugs, including, but not limited to, nutritional media including nutritional supplements, dyes or other tracing media, saline or other hydration media, or the like.
A generalized representation of an infusion media delivery system 10 is shown in
The infusion media delivery system 10 may also include other components coupled for communication with the delivery device 12, including, but not limited to, a sensing arrangement 14 such as a sensor or monitor, a command control device (CCD) 16 and a computer 18. Each of the CCD 16, the computer 18 and the delivery device 12 may include receiver or transceiver electronics that allow communication with other components of the system. The delivery device 12 may include electronics and software for analyzing sensor data and for delivering infusion media according to sensed data and/or pre-programmed delivery routines. Some of the processing, delivery routine storage and control functions may be carried out by the CCD 16 and/or the computer 18, to allow the delivery device 12 to be made with more simplified electronics. However, in other embodiments, the infusion media delivery system 10 may comprise delivery device 12 without any one or more of the other components of the infusion media delivery system 10 shown in
In the generalized system diagram of
The sensing arrangement 14 generally represents the components of the fluid delivery or infusion system 10 configured to sense, detect, measure or otherwise quantify a condition of the user, and may include a sensor, a monitor, or the like, for providing data indicative of the condition that is sensed, detected, measured or otherwise monitored by the sensing arrangement. In this regard, the sensing arrangement 14 may include electronics and enzymes reactive to a biological or physiological condition of the user, such as a blood glucose level, or the like, and provide data indicative of the blood glucose level to the infusion device 12, the CCD 16 and/or the computer 18. For example, the infusion device 12, the CCD 16 and/or the computer 18 may include a display for presenting information or data to the user based on the sensor data received from the sensing arrangement 14, such as, for example, a current glucose level of the user, a graph or chart of the user's glucose level versus time, device status indicators, alert messages, or the like. In other embodiments, the infusion device 12, the CCD 16 and/or the computer 18 may include electronics and software that are configured to analyze sensor data and operate the infusion device 12 to deliver fluid to the body of the user based on the sensor data and/or preprogrammed delivery routines. Thus, in exemplary embodiments, one or more of the infusion device 12, the sensing arrangement 14, the CCD 16, and/or the computer 18 includes a transmitter, a receiver, and/or other transceiver electronics that allow for communication with other components of the infusion system 10, so that the sensing arrangement 14 may transmit sensor data or monitor data to one or more of the infusion device 12, the CCD 16 and/or the computer 18.
Still referring to
In various embodiments, the CCD 16 and/or the computer 18 may include electronics and other components configured to perform processing, delivery routine storage, and to control the infusion device 12 in a manner that is influenced by sensor data measured by and/or received from the sensing arrangement 14. By including control functions in the CCD 16 and/or the computer 18, the infusion device 12 may be made with more simplified electronics. However, in other embodiments, the infusion device 12 may include all control functions, and may operate without the CCD 16 and/or the computer 18. In various embodiments, the CCD 16 may be a portable electronic device. In addition, in various embodiments, the infusion device 12 and/or the sensing arrangement 14 may be configured to transmit data to the CCD 16 and/or the computer 18 for display or processing of the data by the CCD 16 and/or the computer 18.
In some embodiments, the CCD 16 and/or the computer 18 may provide information to the user that facilitates the user's subsequent use of the infusion device 12. For example, the CCD 16 may provide information to the user to allow the user to determine the rate or dose of medication to be administered into the user's body. In other embodiments, the CCD 16 may provide information to the infusion device 12 to autonomously control the rate or dose of medication administered into the body of the user. In some embodiments, the sensing arrangement 14 may be integrated into the CCD 16. Such embodiments may allow the user to monitor a condition by providing, for example, a sample of his or her blood to the sensing arrangement 14 to assess his or her condition. In some embodiments, the sensing arrangement 14 and the CCD 16 may be used for determining glucose levels in the blood and/or body fluids of the user without the use of, or necessity of, a wire or cable connection between the infusion device 12 and the sensing arrangement 14 and/or the CCD 16.
In one or more exemplary embodiments, the sensing arrangement 14 and/or the infusion device 12 are cooperatively configured to utilize a closed-loop system for delivering fluid to the user. Examples of sensing devices and/or infusion pumps utilizing closed-loop systems may be found at, but are not limited to, the following U.S. Pat. Nos. 6,088,608, 6,119,028, 6,589,229, 6,740,072, 6,827,702, 7,323,142, and 7,402,153, all of which are incorporated herein by reference in their entirety. In such embodiments, the sensing arrangement 14 is configured to sense or measure a condition of the user, such as, blood glucose level or the like. The infusion device 12 is configured to deliver fluid in response to the condition sensed by the sensing arrangement 14. In turn, the sensing arrangement 14 continues to sense or otherwise quantify a current condition of the user, thereby allowing the infusion device 12 to deliver fluid continuously in response to the condition currently (or most recently) sensed by the sensing arrangement 14 indefinitely. In some embodiments, the sensing arrangement 14 and/or the infusion device 12 may be configured to utilize the closed-loop system only for a portion of the day, for example only when the user is asleep or awake.
An example of a patch-like delivery device 12 according to an embodiment is shown in
In the illustrated embodiment, the disposable portion of the delivery device 12 comprises a disposable base portion 20 that supports a reservoir 24. The durable portion 22 may comprise a housing that secures onto the base portion 20 and covers the reservoir 24. The durable portion 22 may house a suitable drive device, such as an electrically operated motor (not shown in
The disposable base portion 20 has a bottom surface (facing downward and into the page in
The base portion 20 may include a suitable opening or port 23 for connecting a hollow tube 25 to the reservoir 24, to convey infusion media from the reservoir 24. One end of the tube 25 may have a suitable connector 26, such as, but not limited to a Luer connector or a threaded cap connector having a hollow needle for coupling (in fluid-flow communication) to a corresponding connector 27 on the reservoir 24. Alternatively or in addition, the reservoir 24 may include a septum as part of the connector 27, for receiving an end of a hollow needle. The opening or port on the base portion 20 may be provided with corresponding connector structure, such as, but not limited to a Luer connector receptacle or a threaded receptacle shaped to receive a threaded cap connector. Other embodiments may employ other suitable connectors or connection arrangements for connecting one end of the tube 25 in fluid-flow communication with the reservoir 24.
The other end of the tube 25 may connected to a hollow needle 21 for piercing the patient's skin and conveying infusion media into the patient. The hollow needle 21 may be secured to the patient's skin, for example, by manual application or with the assistance of an insertion tool, such as, but not limited to the insertion tool described in U.S. Patent Application Publication No. 2002/0022855, titled “Insertion Device For An Insertion Set And Method Of Using The Same.” In other embodiments, as described below, a hollow needle and insertion mechanism may be included within the delivery device 12, so as to avoid the need for a port 23, tube 25 and connector 26.
The durable portion 22 of the delivery device 12 includes a housing shell configured to mate with and secure to the disposable base portion 20. The durable portion 22 and base portion 20 may be provided with correspondingly shaped grooves, notches, tabs or other suitable features that allow the two parts to easily snap together, by manually pressing the two portions together in a manner well known in the mechanical arts. In a similar manner, the durable portion 22 and base portion 20 may be separated from each other by manually applying sufficient force to unsnap the two parts from each other. In further embodiments, a suitable seal, such as an o-ring seal, may be placed along the peripheral edge of the base portion 20 and/or the durable portion 22, so as to provide a seal against water between the base portion 20 and the durable portion 22.
The durable portion 22 and base portion 20 may be made of suitably rigid materials that maintain their shape, yet provide sufficient flexibility and resilience to effectively snap together and apart, as described above. The base portion 20 material may be selected for suitable compatibility with the patient's skin. For example, the base portion 20 and the durable portion 22 of the delivery device 12 may be made of any suitable plastic, metal, composite material or the like. The base portion 20 may be made of the same type of material or a different material relative to the durable portion 22. The base portion and durable portions may be manufactured by injection molding or other molding processes, machining processes or combinations thereof.
For example, the base portion 20 may be made of a relatively flexible material, such as a flexible silicon, plastic, rubber, synthetic rubber or the like. By forming the base portion of a material capable of flexing with the patient's skin, a greater level of patient comfort may be achieved when the base portion is secured to the patient's skin. Also, a flexible base portion 20 can result in an increase in the site options on the patient's body at which the base portion 20 may be secured.
In the embodiment illustrated in
The sensor 14 may be an external sensor that secures to the patient's skin or, in other embodiments, may be an implantable sensor that is located in an implant site within the patient. In the illustrated example of
While the embodiment shown in
As described above, by separating disposable elements of the delivery device 12 from durable elements, the disposable elements may be arranged on the disposable base portion 20, while durable elements may be arranged within a separable durable portion 22. In this regard, after one (or a prescribed number) of uses of the delivery device 12, the disposable base portion 20 may be separated from the durable portion 22, so that the disposable base portion 20 may be disposed of in a proper manner. The durable portion 22 may, then, be mated with a new (un-used) disposable base portion 20 for further delivery operation with a patient.
The reservoir 24 may be supported by the disposable base portion 20 in any suitable manner. The reservoir 24 may be provided as a cartridge or generally cylindrical canister for containing fluidic infusion media. For example, the base portion 20 may be provided with projections or struts, or a trough feature for holding a cartridge-type reservoir in a manner that allows a user to readily remove the reservoir from the base portion and re-install a new or refilled reservoir, when replacement or re-filling is needed, as described with respect to further embodiments below. Alternatively, or in addition, the reservoir 24 may be secured to the base portion 20 by a suitable adhesive or other coupling structure. The reservoir 24 has a port and may be supported by the base portion 20 in a position at which a connector 26 may engage or otherwise come into fluid flow communication with the reservoir port, when the connector 26 is connected to the port 23 on the base portion 20.
The durable portion 22 of the delivery device 12 may include a motor or other force-applying mechanism, for applying a force to the infusion media within the reservoir 24 to force fluidic infusion media out of the reservoir 24 and into the needle 27, for delivery to the patient. For example, an electrically driven motor may be mounted within the durable portion 22 with appropriate linkage for causing the motor to operably engage a piston of the reservoir and drive the reservoir piston in a direction to cause the fluidic pressure within the reservoir 24 to increase and thereby force fluidic infusion media out of the reservoir port, into the tube 25 and needle 27. The motor may be arranged within the durable portion 22 and the reservoir may be correspondingly arranged on the disposable base portion 20, such that the operable engagement of the motor with the reservoir piston (e.g., through appropriate linkage) occurs automatically upon the patient-user snap fitting the durable portion 22 onto the disposable base portion 20 of the delivery device 12.
While
The illustrated embodiment of the infusion set 104 includes, without limitation: a length of tubing 110; an infusion unit 112 coupled to the distal end of the tubing 110; and a connector 114 coupled to the proximal end of the tubing 110. The fluid infusion delivery device 12 is designed to be carried or worn by the patient, and the infusion set 104 terminates at the infusion unit 112 such that the fluid infusion delivery device 12 can deliver fluid to the body of the patient via the tubing 110. The infusion unit 112 includes a cannula (hidden from view in
The infusion set 104 defines a fluid flow path that fluidly couples a fluid reservoir to the infusion unit 112. The connector 114 mates with and couples to a section of the fluid reservoir (not shown), which in turn is coupled to a housing 120 of the fluid infusion delivery device 12. The connector 114 establishes the fluid path from the fluid reservoir to the tubing 110. Actuation of the fluid infusion delivery device 12 causes the medication fluid to be expelled from the fluid reservoir, through the infusion set 104, and into the body of the patient via the infusion unit 112 and cannula at the distal end of the tubing 110. Accordingly, when the connector 114 is installed as depicted in
The fluid infusion delivery device 12 includes a radio frequency (RF) antenna to support wireless data communication with other devices, systems, and/or components. The RF antenna can be located inside the housing 120 or it can be integrally formed with the housing 120. Accordingly, the RF antenna is hidden from view in
As may be understood from
In
As shown, a fluid reservoir 24 is received by a portion 22 of the delivery device. The reservoir 24 is bounded by a wall 220. Also, a testing chamber 225 is provided in the identifying system 200. The testing chamber 225 is bound by a wall 230. In an exemplary embodiment, at least a portion of the wall 230 is transparent. For example, the wall 230 may be formed from a transparent material such as clear polycarbonate, polypropylene, polyurethane/polypropylene, or other clear polymeric material. Alternatively or additionally, the wall 230 may be formed with a transparent window formed from clear polycarbonate, polypropylene, polyurethane/polypropylene, or other clear polymeric material. In certain embodiments, the wall 220 of the reservoir 24 and the wall 230 of the testing chamber 225 are integrally formed. In other words, the testing chamber 225 in certain embodiments is realized as an extension or a pocket of the reservoir 24.
As shown, the reservoir 24 and testing chamber 225 are selectively coupled by a one-way valve that allows for selective fluid flow from the reservoir 24 to the testing chamber 225 and which prevents back flow from the testing chamber 225 to the reservoir 24. Suitable one-way valves may include ball check valves, diaphragm check valves, swing/tilting check valves, stop-check valves, lift-check valves, in-line check valves, duckbill valves, pneumatic non-return valves, or others.
In the illustrated embodiment, an indicator 240 is located in the testing chamber 225. In an exemplary embodiment, the indicator is an indicator chemical, such as dithizone, pseudoisocyanin compounds, aldehyde fuchsin, Victoria 4R blue, various chromophore/fluorophore labelled insulin antibodies, and others. In other embodiments, the indicator 240 can be a small piece of carrier material having an indicator chemical applied to it and/or having an indicator chemical impregnated therein. In yet other embodiments, the indicator 240 can be realized as or attached to an inner surface of the chamber 225. The indicator 240 may be provided in solid or fluid phase. During manufacture of the reservoir 24 and testing chamber 225, the indicator 240 is sealed in the testing chamber 225 by the one-way valve.
An exemplary indicator 240 exhibits and/or causes the infusate to exhibit a visual change when the indicator 240 is contacted by the infusate. For example, the indicator 240 may exhibit and/or cause the infusate to exhibit a color change when the indicator 240 is contacted by the infusate. In exemplary embodiments, the indicator causes a change to a first color when contacted with a first infusate, such as U-100 insulin, a change to a second color when contacted with a second infusate, such as U-200 insulin, a change to a third color when contacted with a third infusate, such as U-300 insulin, or a change to a fourth color when contacted with a fourth infusate, such as U-500 insulin. For example, if the concentration of the indicator (e.g. dithizone, a light blue color) is fixed, the color developed by mixing the indicator with insulin at various concentrations may vary from light pink to dark pink. If measured at a wavelength of 530 nm, the absorbance will be linear to insulin concentration for a properly designed test system. If the indicator is mixed with other non-insulin formulations, the resulting color will not be pink.
In
As shown, the detector arrangement 210 further includes a printed circuit board (PCB) 250. The receiver element 245 is coupled to the PCB 250. The PCB 250 may be part of receiver electronics. The PCB 250 may be in communication with sensing arrangement 14, CCD 16 or computer 18 of
In
In an exemplary embodiment, the identifier element 255 analyses the signal received from the receiver element 245 by comparing the image data therein with image data from a library of previously tested infusates and their associated image data. For this reason, the identifier element 255 may include or be in electronic communication with a memory storage or library 260 storing the image data of known infusates and concentrations of infusates.
As shown, the receiver element 245, identifier element 255 and memory storage 260 are coupled to the PCB 250 such that the PCB 250 may activate and identification operation. For example, the PCB 250 may active an identification operation when the reservoir is filled, when the user prompts the delivery device, or during preset time intervals. Further, through communication with the sensing arrangement 14, CCD 16 or computer 18, the PCB 250 may verify that the identified infusate is the proper infusate, i.e., the expected infusate. Alternatively, if the identified infusate is different from the expected infusate, the PCB 250 may communicate the identity of the infusate and the infusate concentration to the sensing arrangement 14, CCD 16 or computer 18 so that a fluid delivery regime may be modified for use with the identified infusate.
The detector arrangement 310 includes a transceiver 340 provided with both a transmitter element and a receiver element. The transceiver 340 may be aligned with a window in the wall 230, if provided, so that the transceiver 340 may transmit a beam of energy through the window, or through a transparent or translucent portion of wall 230, and into contact with an infusate located in the testing chamber 225, and may receive a reflected beam of energy from the infusate back to the transceiver 340.
As further shown, the transceiver 340 is mounted to a printed circuit board (PCB) 350 that may be part of receiver electronics located within the durable portion 22. The PCB 350 may be an additional PCB, or may be part of PCB 250. The PCB 350 may be in communication with sensing arrangement 14, CCD 16 or computer 18 of
While
As contemplated herein, the detector arrangement 310, including transmitter and receiver elements of the transceiver 340, may be located in any suitable location along the fluid path of a fluid delivery device 12. For example, the detector arrangement 310 could be provided to transmit a beam of energy into contact with an infusate located in the reservoir 24 and to receive a reflected beam of energy from the infusate back to the transceiver 340. As used herein, any of the components containing or delivering a flow of an infusate are considered a conduit where a detector arrangement 310 may be located.
Further, a fluid delivery device 12 may be provided with more than one detector arrangements 310 and/or more than one detector arrangements 210. In an exemplary embodiment, each of the detector arrangements 310 transmits a beam of energy into the fluid orthogonally to the direction of fluid flow or to the wall of the vessel through which the fluid flows.
Detector arrangements 310 may identify the composition and concentration of a fluid or infusate within a conduit, such as a reservoir, hollow tube, or other fluid path, that is bound by a wall. In certain embodiments, the wall may be transparent and not include a separate distinct window. In embodiments, a beam of energy, such as IR, NIR, or UV energy, is transmitted into the conduit from a transmitter element of the transceiver 340 and interacts with the infusate and any foreign matter therein. For example, different portions or wavelength ranges of the beam of energy may be absorbed, refracted or reflected. In certain embodiments, a resulting beam of energy passes out of the conduit and is received by a receiver element of the transceiver 340 as a signal. The signal can be analyzed to determine the composition and concentration of the infusate and whether foreign matter is present in the infusate.
Upon filling the reservoir 24 with infusate, the one-way valve permits a portion of the infusate to enter the testing chamber 225 and contact the indicator. Upon contact therebetween, a visual change such as a color change is exhibited, such as at step 406.
Then, the user may couple the infusate reservoir with the fluid delivery device at step 408. Upon coupling, the identification process may be automatically initiated to confirm that the correct infusate is loaded in the fluid delivery device. Alternatively, the identification process may be initiated by the user or during preset time intervals. In either case, the identification process includes capturing an image of the testing chamber including the indicator and infusate, or a solution thereof, at step 410. Further, the method 400 includes generating a signal including image data at step 412. The signal may be generated by the receiver element or camera and then communicated to the identifier element.
At step 414, the method analyzes the image data, such as by comparing the image data with stored image data associated with known infusates at known concentrations. In this manner, the identity of the infusate and concentration of the infusate received in the reservoir can be identified.
At step 416, the method queries whether, based on the image data comparison, the proper or expected infusate is loaded in the fluid delivery device. If not, the PCB, sensing arrangement, CCD or computer may automatically alert the user and/or disable infusion of the infusate from the fluid delivery device or modify fluid delivery to an appropriate process for the identified infusate at step 418. On the other hand, if the correct infusate is loaded, the PCB, sensing arrangement, CCD or computer may confirm that the correct infusate is loaded and allow the fluid delivery device to proceed with an infusion process at step 420.
At step 508, the signal of the resulting beam of energy is communicated from the receiver element to an identifier element. For example, the signal may be wirelessly communicated from the receiver element to the identifier element. The identifier element may be contained within a PCB, sensing arrangement, CCD or computer. The signal is or includes spectroscopic data that may be represented by a spectrum that may be plotted as a graph of energy absorbance (or transmittance) on the vertical axis vs. frequency or wavelength on the horizontal axis.
The identifier element includes or is coupled to a memory storage or library of spectra of known, i.e., previously tested compositions and concentrations. The memory stores data associated with selected fluids for comparison with detected characteristics of the signal. At step 510, the spectrum of the signal is compared to the spectra of known compositions and concentrations. For example, the identifier element may use the stored data to identify the infusate based on the received signal. As is known in absorptive spectroscopic analysis, different compositions and different concentrations of those compositions exhibit unique spectra or signature spectra. For example, differing values of intensity of radiation at specific wavelengths or frequencies or over specific ranges of wavelengths or frequencies may indicate that the beam of energy passed through a specific concentration of a specific composition. Spectral different regions of a reflective NIR/IR spectra graph of fluid-path materials and infusates (insulin formulations) may be used for infusate/bubble tracking. Spectroscopic signals at various wavelengths may be orthogonally used for better identification accuracy.
At step 512, the method queries whether, based on the signal spectrum comparison, the proper or expected infusate is loaded in the fluid delivery device. If not, the PCB, sensing arrangement, CCD or computer may automatically alert the user and/or disable infusion of the infusate from the fluid delivery device at step 514. On the other hand, if the correct infusate is loaded, the PCB, sensing arrangement, CCD or computer may confirm that the correct infusate is loaded and allow the fluid delivery device to proceed with an infusion process at step 516.
While the subject matter is described above primarily in the context of a reservoir containing insulin for regulating a glucose level of a user, the subject matter described herein is not limited to any type of media dispensed from or otherwise provided by the reservoir, and the subject matter may be implemented with other medical devices or electronic devices other than fluid infusion devices. For example, any electronic device could be configured to analyze and identify the composition and concentration of a fluid contained in a reservoir through selective contact with an indicator, image capture of the fluid and indicator, and image analysis.
For the sake of brevity, conventional techniques related to glucose sensing and/or monitoring, closed-loop glucose control, sensor calibration, electrical signals and related processing, electrical interconnects or interfaces, packaging, fluid communications, fluid monitoring or measuring, and other functional aspects of the subject matter may not be described in detail herein. In addition, certain terminology may also be used in the herein for the purpose of reference only, and thus is not intended to be limiting. For example, terms such as “first”, “second”, and other such numerical terms referring to structures do not imply a sequence or order unless clearly indicated by the context. The foregoing description may also refer to elements or nodes or features being “connected” or “coupled” together. As used herein, unless expressly stated otherwise, “coupled” means that one element/node/feature is directly or indirectly joined to (or directly or indirectly communicates with) another element/node/feature, and not necessarily mechanically.
While at least one exemplary embodiment has been presented in the foregoing detailed description, it should be appreciated that a vast number of variations exist. It should also be appreciated that the exemplary embodiment or embodiments described herein are not intended to limit the scope, applicability, or configuration of the claimed subject matter in any way. For example, the subject matter described herein is not necessarily limited to the infusion devices and related systems described herein. Moreover, the foregoing detailed description will provide those skilled in the art with a convenient road map for implementing the described embodiment or embodiments. It should be understood that various changes can be made in the function and arrangement of elements without departing from the scope defined by the claims, which includes known equivalents and foreseeable equivalents at the time of filing this patent application. Accordingly, details of the exemplary embodiments or other limitations described above should not be read into the claims absent a clear intention to the contrary.
Number | Name | Date | Kind |
---|---|---|---|
3631847 | Hobbs, II | Jan 1972 | A |
4212738 | Henne | Jul 1980 | A |
4270532 | Franetzki et al. | Jun 1981 | A |
4282872 | Franetzki et al. | Aug 1981 | A |
4373527 | Fischell | Feb 1983 | A |
4395259 | Prestele et al. | Jul 1983 | A |
4433072 | Pusineri et al. | Feb 1984 | A |
4443218 | Decant, Jr. et al. | Apr 1984 | A |
4494950 | Fischell | Jan 1985 | A |
4542532 | McQuilkin | Sep 1985 | A |
4550731 | Batina et al. | Nov 1985 | A |
4559037 | Franetzki et al. | Dec 1985 | A |
4562751 | Nason et al. | Jan 1986 | A |
4671288 | Gough | Jun 1987 | A |
4678408 | Nason et al. | Jul 1987 | A |
4685903 | Cable et al. | Aug 1987 | A |
4731051 | Fischell | Mar 1988 | A |
4731726 | Allen, III | Mar 1988 | A |
4781798 | Gough | Nov 1988 | A |
4803625 | Fu et al. | Feb 1989 | A |
4809697 | Causey, III et al. | Mar 1989 | A |
4826810 | Aoki | May 1989 | A |
4871351 | Feingold | Oct 1989 | A |
4898578 | Rubalcaba, Jr. | Feb 1990 | A |
5003298 | Havel | Mar 1991 | A |
5011468 | Lundquist et al. | Apr 1991 | A |
5019974 | Beckers | May 1991 | A |
5050612 | Matsumura | Sep 1991 | A |
5078683 | Sancoff et al. | Jan 1992 | A |
5080653 | Voss et al. | Jan 1992 | A |
5097122 | Colman et al. | Mar 1992 | A |
5100380 | Epstein et al. | Mar 1992 | A |
5101814 | Palti | Apr 1992 | A |
5108819 | Heller et al. | Apr 1992 | A |
5153827 | Coutre et al. | Oct 1992 | A |
5165407 | Wilson et al. | Nov 1992 | A |
5247434 | Peterson et al. | Sep 1993 | A |
5262035 | Gregg et al. | Nov 1993 | A |
5262305 | Heller et al. | Nov 1993 | A |
5264104 | Gregg et al. | Nov 1993 | A |
5264105 | Gregg et al. | Nov 1993 | A |
5284140 | Allen et al. | Feb 1994 | A |
5299571 | Mastrototaro | Apr 1994 | A |
5307263 | Brown | Apr 1994 | A |
5317506 | Coutre et al. | May 1994 | A |
5320725 | Gregg et al. | Jun 1994 | A |
5322063 | Allen et al. | Jun 1994 | A |
5338157 | Blomquist | Aug 1994 | A |
5339821 | Fujimoto | Aug 1994 | A |
5341291 | Roizen et al. | Aug 1994 | A |
5350411 | Ryan et al. | Sep 1994 | A |
5356786 | Heller et al. | Oct 1994 | A |
5357427 | Langen et al. | Oct 1994 | A |
5368562 | Blomquist et al. | Nov 1994 | A |
5370622 | Livingston et al. | Dec 1994 | A |
5371687 | Holmes, II et al. | Dec 1994 | A |
5376070 | Purvis et al. | Dec 1994 | A |
5390671 | Lord et al. | Feb 1995 | A |
5391250 | Cheney, II et al. | Feb 1995 | A |
5403700 | Heller et al. | Apr 1995 | A |
5411647 | Johnson et al. | May 1995 | A |
5482473 | Lord et al. | Jan 1996 | A |
5485408 | Blomquist | Jan 1996 | A |
5505709 | Funderburk et al. | Apr 1996 | A |
5497772 | Schulman et al. | May 1996 | A |
5543326 | Heller et al. | Aug 1996 | A |
5569186 | Lord et al. | Oct 1996 | A |
5569187 | Kaiser | Oct 1996 | A |
5573506 | Vasko | Nov 1996 | A |
5582593 | Hultman | Dec 1996 | A |
5586553 | Halili et al. | Dec 1996 | A |
5593390 | Castellano et al. | Jan 1997 | A |
5593852 | Heller et al. | Jan 1997 | A |
5594638 | Illiff | Jan 1997 | A |
5609060 | Dent | Mar 1997 | A |
5626144 | Tacklind et al. | May 1997 | A |
5630710 | Tune et al. | May 1997 | A |
5643212 | Coutre et al. | Jul 1997 | A |
5660163 | Schulman et al. | Aug 1997 | A |
5660176 | Iliff | Aug 1997 | A |
5665065 | Colman et al. | Sep 1997 | A |
5665222 | Heller et al. | Sep 1997 | A |
5685844 | Marttila | Nov 1997 | A |
5687734 | Dempsey et al. | Nov 1997 | A |
5704366 | Tacklind et al. | Jan 1998 | A |
5750926 | Schulman et al. | May 1998 | A |
5754111 | Garcia | May 1998 | A |
5764159 | Neftel | Jun 1998 | A |
5772635 | Dastur et al. | Jun 1998 | A |
5779665 | Mastrototaro et al. | Jul 1998 | A |
5788669 | Peterson | Aug 1998 | A |
5791344 | Schulman et al. | Aug 1998 | A |
5800420 | Gross et al. | Sep 1998 | A |
5807336 | Russo et al. | Sep 1998 | A |
5814015 | Gargano et al. | Sep 1998 | A |
5822715 | Worthington et al. | Oct 1998 | A |
5832448 | Brown | Nov 1998 | A |
5840020 | Heinonen et al. | Nov 1998 | A |
5861018 | Feierbach et al. | Jan 1999 | A |
5868669 | Iliff | Feb 1999 | A |
5871465 | Vasko | Feb 1999 | A |
5879163 | Brown et al. | Mar 1999 | A |
5885245 | Lynch et al. | Mar 1999 | A |
5897493 | Brown | Apr 1999 | A |
5899855 | Brown | May 1999 | A |
5904708 | Goedeke | May 1999 | A |
5913310 | Brown | Jun 1999 | A |
5917346 | Gord | Jun 1999 | A |
5918603 | Brown | Jul 1999 | A |
5925021 | Castellano et al. | Jul 1999 | A |
5933136 | Brown | Aug 1999 | A |
5935099 | Peterson et al. | Aug 1999 | A |
5940801 | Brown | Aug 1999 | A |
5956501 | Brown | Sep 1999 | A |
5960403 | Brown | Sep 1999 | A |
5965380 | Heller et al. | Oct 1999 | A |
5972199 | Heller et al. | Oct 1999 | A |
5978236 | Faberman et al. | Nov 1999 | A |
5997476 | Brown | Dec 1999 | A |
5999848 | Gord et al. | Dec 1999 | A |
5999849 | Gord et al. | Dec 1999 | A |
6009339 | Bentsen et al. | Dec 1999 | A |
6032119 | Brown et al. | Feb 2000 | A |
6043437 | Schulman et al. | Mar 2000 | A |
6081736 | Colvin et al. | Jun 2000 | A |
6083710 | Heller et al. | Jul 2000 | A |
6088608 | Schulman et al. | Jul 2000 | A |
6101478 | Brown | Aug 2000 | A |
6103033 | Say et al. | Aug 2000 | A |
6119028 | Schulman et al. | Sep 2000 | A |
6120676 | Heller et al. | Sep 2000 | A |
6121009 | Heller et al. | Sep 2000 | A |
6134461 | Say et al. | Oct 2000 | A |
6143164 | Heller et al. | Nov 2000 | A |
6162611 | Heller et al. | Dec 2000 | A |
6175752 | Say et al. | Jan 2001 | B1 |
6183412 | Benkowski et al. | Feb 2001 | B1 |
6246992 | Brown | Jun 2001 | B1 |
6259937 | Schulman et al. | Jul 2001 | B1 |
6329161 | Keller et al. | Dec 2001 | B1 |
6408330 | DeLaHuerga | Jun 2002 | B1 |
6424847 | Mastrototaro et al. | Jul 2002 | B1 |
6472122 | Schulman et al. | Oct 2002 | B1 |
6484045 | Holker et al. | Nov 2002 | B1 |
6484046 | Say et al. | Nov 2002 | B1 |
6485465 | Moberg et al. | Nov 2002 | B2 |
6503381 | Gotoh et al. | Jan 2003 | B1 |
6514718 | Heller et al. | Feb 2003 | B2 |
6544173 | West et al. | Apr 2003 | B2 |
6553263 | Meadows et al. | Apr 2003 | B1 |
6554798 | Mann et al. | Apr 2003 | B1 |
6558320 | Causey, III et al. | May 2003 | B1 |
6558351 | Steil et al. | May 2003 | B1 |
6560741 | Gerety et al. | May 2003 | B1 |
6565509 | Say et al. | May 2003 | B1 |
6579690 | Bonnecaze et al. | Jun 2003 | B1 |
6589229 | Connelly et al. | Jul 2003 | B1 |
6591125 | Buse et al. | Jul 2003 | B1 |
6592745 | Feldman et al. | Jul 2003 | B1 |
6605200 | Mao et al. | Aug 2003 | B1 |
6605201 | Mao et al. | Aug 2003 | B1 |
6607658 | Heller et al. | Aug 2003 | B1 |
6616819 | Liamos et al. | Sep 2003 | B1 |
6618934 | Feldman et al. | Sep 2003 | B1 |
6623501 | Heller et al. | Sep 2003 | B2 |
6641533 | Causey, III et al. | Nov 2003 | B2 |
6654625 | Say et al. | Nov 2003 | B1 |
6659980 | Moberg et al. | Dec 2003 | B2 |
6671554 | Gibson et al. | Dec 2003 | B2 |
6676816 | Mao et al. | Jan 2004 | B2 |
6689265 | Heller et al. | Feb 2004 | B2 |
6728576 | Thompson et al. | Apr 2004 | B2 |
6733471 | Ericson et al. | May 2004 | B1 |
6740072 | Starkweather et al. | May 2004 | B2 |
6746582 | Heller et al. | Jun 2004 | B2 |
6747556 | Medema et al. | Jun 2004 | B2 |
6749740 | Liamos et al. | Jun 2004 | B2 |
6752787 | Causey, III et al. | Jun 2004 | B1 |
6809653 | Mann et al. | Oct 2004 | B1 |
6817990 | Yap et al. | Nov 2004 | B2 |
6827702 | Lebel et al. | Dec 2004 | B2 |
6881551 | Heller et al. | Apr 2005 | B2 |
6892085 | McIvor et al. | May 2005 | B2 |
6893545 | Gotoh et al. | May 2005 | B2 |
6895263 | Shin et al. | May 2005 | B2 |
6916159 | Rush et al. | Jul 2005 | B2 |
6932584 | Gray et al. | Aug 2005 | B2 |
6932894 | Mao et al. | Aug 2005 | B2 |
6942518 | Liamos et al. | Sep 2005 | B2 |
7153263 | Carter et al. | Dec 2006 | B2 |
7153289 | Vasko | Dec 2006 | B2 |
7323142 | Pendo et al. | Jan 2008 | B2 |
7365847 | Auton | Apr 2008 | B2 |
7396330 | Banet et al. | Jul 2008 | B2 |
7402153 | Steil et al. | Jul 2008 | B2 |
7621893 | Moberg et al. | Nov 2009 | B2 |
8674288 | Hanson et al. | Mar 2014 | B2 |
20010044731 | Coffman et al. | Nov 2001 | A1 |
20020013518 | West et al. | Jan 2002 | A1 |
20020022855 | Bobroff et al. | Feb 2002 | A1 |
20020055857 | Mault et al. | May 2002 | A1 |
20020082665 | Haller et al. | Jun 2002 | A1 |
20020137997 | Mastrototaro et al. | Sep 2002 | A1 |
20020161288 | Shin et al. | Oct 2002 | A1 |
20030060765 | Campbell et al. | Mar 2003 | A1 |
20030078560 | Miller et al. | Apr 2003 | A1 |
20030088166 | Say et al. | May 2003 | A1 |
20030144581 | Conn et al. | Jul 2003 | A1 |
20030152823 | Heller | Aug 2003 | A1 |
20030176183 | Drucker et al. | Sep 2003 | A1 |
20030188427 | Say et al. | Oct 2003 | A1 |
20030199744 | Buse et al. | Oct 2003 | A1 |
20030208113 | Mault et al. | Nov 2003 | A1 |
20030220552 | Reghabi et al. | Nov 2003 | A1 |
20040061232 | Shah et al. | Apr 2004 | A1 |
20040061234 | Shah et al. | Apr 2004 | A1 |
20040064133 | Miller et al. | Apr 2004 | A1 |
20040064156 | Shah et al. | Apr 2004 | A1 |
20040073095 | Causey, III et al. | Apr 2004 | A1 |
20040074785 | Holker et al. | Apr 2004 | A1 |
20040093167 | Braig et al. | May 2004 | A1 |
20040097796 | Berman et al. | May 2004 | A1 |
20040102683 | Khanuja et al. | May 2004 | A1 |
20040111017 | Say et al. | Jun 2004 | A1 |
20040122353 | Shahmirian et al. | Jun 2004 | A1 |
20040167465 | Mihai et al. | Aug 2004 | A1 |
20040193453 | Butterfield et al. | Sep 2004 | A1 |
20040263354 | Mann et al. | Dec 2004 | A1 |
20050038331 | Silaski et al. | Feb 2005 | A1 |
20050038680 | McMahon et al. | Feb 2005 | A1 |
20050154271 | Rasdal et al. | Jul 2005 | A1 |
20050192557 | Brauker et al. | Sep 2005 | A1 |
20060229694 | Schulman et al. | Oct 2006 | A1 |
20060238333 | Welch et al. | Oct 2006 | A1 |
20060293571 | Bao et al. | Dec 2006 | A1 |
20070088521 | Shmueli et al. | Apr 2007 | A1 |
20070135866 | Baker et al. | Jun 2007 | A1 |
20080154503 | Wittenber et al. | Jun 2008 | A1 |
20090081951 | Erdmann et al. | Mar 2009 | A1 |
20090082635 | Baldus et al. | Mar 2009 | A1 |
20100121170 | Rule | May 2010 | A1 |
20110105952 | Bernstein | May 2011 | A1 |
20120184907 | Smith | Jul 2012 | A1 |
20120232362 | Gable et al. | Sep 2012 | A1 |
20140128960 | Greenslet | May 2014 | A1 |
20150314068 | Alderete, Jr. | Nov 2015 | A1 |
20160346456 | Cefai | Dec 2016 | A1 |
Number | Date | Country |
---|---|---|
4329229 | Mar 1995 | DE |
0319268 | Nov 1988 | EP |
0806738 | Nov 1997 | EP |
0880936 | Dec 1998 | EP |
1338295 | Aug 2003 | EP |
1631036 | Mar 2006 | EP |
2218831 | Nov 1989 | GB |
WO 9620745 | Jul 1996 | WO |
WO 963724 6 | Nov 1996 | WO |
WO 9636389 | Nov 1996 | WO |
WO 9721456 | Jun 1997 | WO |
WO 9820439 | May 1998 | WO |
WO 9824358 | Jun 1998 | WO |
WO 9842407 | Oct 1998 | WO |
WO 9849659 | Nov 1998 | WO |
WO 9859487 | Dec 1998 | WO |
WO 9908183 | Feb 1999 | WO |
WO 9910801 | Mar 1999 | WO |
WO 9918532 | Apr 1999 | WO |
WO 9922236 | May 1999 | WO |
WO 0010628 | Mar 2000 | WO |
WO 0019887 | Apr 2000 | WO |
WO 0048112 | Aug 2000 | WO |
WO 02058537 | Aug 2002 | WO |
PCTUS0203299 | Oct 2002 | WO |
WO 03001329 | Jan 2003 | WO |
WO 03094090 | Nov 2003 | WO |
WO 2005065538 | Jul 2005 | WO |
Entry |
---|
(Animas Corporation, 1999). Animas . . . bringing new life to insulin therapy. |
Bode B W, et al. (1996). Reduction in Severe Hypoglycemia with Long-Term Continuous Subcutaneous Insulin Infusion in Type I Diabetes. Diabetes Care, vol. 19, No. 4, 324-327. |
Boland E (1998). Teens Pumping it Up! Insulin Pump Therapy Guide for Adolescents. 2nd Edition. |
Brackenridge B P (1992). Carbohydrate Gram Counting A Key to Accurate Mealtime Boluses in Intensive Diabetes Therapy. Practical Diabetology, vol. 11, No. 2, pp. 22-28. |
Brackenridge, B P et al. (1995). Counting Carbohydrates How to Zero in on Good Control. MiniMed Technologies Inc. |
Farkas-Hirsch R et al. (1994). Continuous Subcutaneous Insulin Infusion: A Review of the Past and Its Implementation for the Future. Diabetes Spectrum From Research to Practice, vol. 7, No. 2, pp. 80-84, 136-138. |
Hirsch I B et al. (1990). Intensive Insulin Therapy for Treatment of Type I Diabetes. Diabetes Care, vol. 13, No. 12, pp. 1265-1283. |
Kulkarni K et al. (1999). Carbohydrate Counting A Primer for Insulin Pump Users to Zero in on Good Control. MiniMed Inc. |
Marcus A O et al. (1996). Insulin Pump Therapy Acceptable Alternative to Injection Therapy. Postgraduate Medicine, vol. 99, No. 3, pp. 125-142. |
Reed J et al. (1996). Voice of the Diabetic, vol. 11, No. 3, pp. 1-38. |
Skyler J S (1989). Continuous Subcutaneous Insulin Infusion [CSII] With External Devices: Current Status. Update in Drug Delivery Systems, Chapter 13, pp. 163-183. Futura Publishing Company. |
Skyler J S et al. (1995). The Insulin Pump Therapy Book Insights from the Experts. MiniMed⋅Technologies. |
Strowig S M (1993). Initiation and Management of Insulin Pump Therapy. The Diabetes Educator, vol. 19, No. 1, pp. 50-60. |
Walsh J, et al. (1989). Pumping Insulin: The Art of Using an Insulin Pump. Published by MiniMed⋅Technologies. |
(Intensive Diabetes Management, 1995). Insulin Infusion Pump Therapy. pp. 66-78. |
Disetronic My Choice™ D-TRON™ Insulin Pump Reference Manual. (Publication or release date no later than Nov. 2007). |
Disetronic H-TRON® plus Quick Start Manual. (Publication or release date no later than Nov. 2007). |
Disetronic My Choice H-TRONplus Insulin Pump Reference Manual. (Publication or release date no later than Nov. 2007). |
Disetronic H-TRON® plus Reference Manual. (Publication or release date no later than Nov. 2007). |
(MiniMed, 1996). The MiniMed 506. 7 pages. Retrieved on Sep. 16, 2003 from the World Wide Web: http://web.archive.org/web/19961111054527/www.minimed.com/files/506_pic.htm. |
(Minimed, 1997). MiniMed 507 Specifications. 2 pages. Retrieved on Sep. 16, 2003 from the World Wide Web: http://web.archive.org/web/19970124234841/www.minimed.com/files/mmn075.htm. |
(Minimed, 1996). FAQ: The Practical Things . . . pp. 1-4. Retrieved on Sep. 16, 2003 from the World Wide Web: http://web.archive.org/web/19961111054546/www.minimed.com/files/faq_pract.htm. |
(MiniMed, 1997). Wanted: a Few Good Belt Clips! 1 page. Retrieved on Sep. 16, 2003 from the World Wide Web: http://web.archive.org/web/19970124234559/www.minimed.com/files/mmn002.htm. |
(MiniMed Technologies, 1994). MiniMed 506 Insulin Pump User's Guide. |
(MiniMed Technologies, 1994). MiniMed™ Dosage Calculator Initial Meal Bolus Guidelines/MiniMed™ Dosage Calculator Initial Basal Rate Guidelines Percentage Method. 4 pages. |
(Minimed, 1996). MiniMed™ 507 Insulin Pump User's Guide. |
(Minimed, 1997). MiniMed™ 507 Insulin Pump User's Guide. |
(Minimed, 1998). MiniMed 507C Insulin Pump User's Guide. |
(MiniMed International, 1998). MiniMed 507C Insulin Pump For those who appreciate the difference. |
(MiniMed Inc., 1999). MiniMed 508 Flipchart Guide to Insulin Pump Therapy. |
(MiniMed Inc., 1999). Insulin Pump Comparison / Pump Therapy Will Change Your Life. |
(Minimed, 2000). MiniMed® 508 User's Guide. |
(MiniMed Inc., 2000). MiniMed® Now [I] Can Meal Bolus Calculator / MiniMed® Now [I] Can Correction Bolus Calculator. |
(MiniMed Inc., 2000). Now [I] Can MiniMed Pump Therapy. |
(MiniMed Inc., 2000). Now [I] Can MiniMed Diabetes Management. |
(Medtronic MiniMed, 2002). The 508 Insulin Pump A Tradition of Excellence. |
(Medtronic MiniMed, 2002). Medtronic MiniMed Meal Bolus Calculator and Correction Bolus Calculator. International Version. |
Abel, P., et al., “Experience with an implantable glucose sensor as a prerequiste of an artificial beta cell,” Biomed. Biochim. Acta 43 (1984) 5, pp. 577-584. |
Bindra, Dilbir S., et al., “Design and in Vitro Studies of a Needle-Type Glucose Sensor for a Subcutaneous Monitoring,” American Chemistry Society, 1991, 63, pp. 1692-1696. |
Boguslavsky, Leonid, et al., “Applications of redox polymers in biosensors,” Sold State Ionics 60, 1993, pp. 189-197. |
Geise, Robert J., et al., “Electropolymerized 1,3-diaminobenzene for the construction of a 1,1′-dimethylferrocene mediated glucose biosensor,” Analytica Chimica Acta, 281, 1993, pp. 467-473. |
Gernet, S., et al., “A Planar Glucose Enzyme Electrode,” Sensors and Actuators, 17, 1989, pp. 537-540. |
Gernet, S., et al., “Fabrication and Characterization of a Planar Electromechanical Cell and its Application as a Glucose Sensor,” Sensors and Actuators, 18, 1989, pp. 59-70. |
Gorton, L., et al., “Amperometric Biosensors Based on an Apparent Direct Electron Transfer Between Electrodes and Immobilized Peroxiases,” Analyst, Aug. 1991, vol. 117, pp. 1235-1241. |
Gorton, L., et al., “Amperometric Glucose Sensors Based on Immobilized Glucose-Oxidizing Enymes and Chemically Modified Electrodes,” Analytica Chimica Acta, 249, 1991, pp. 43-54. |
Gough, D. A., et al., “Two-Dimensional Enzyme Electrode Sensor for Glucose,” Analytical Chemistry, vol. 57, No. 5, 1985, pp. 2351-2357. |
Gregg, Brian A., et al., “Cross-Linked Redox Gels Containing Glucose Oxidase for Amperometric Biosensor Applications,” Analytical Chemistry, 62, pp. 258-263. (Publication or release date no later than Nov. 2007). |
Gregg, Brian A., et al., “Redox Polymer Films Containing Enzymes. 1. A Redox-Conducting Epoxy Cement: Synthesis, Characterization, and Electrocatalytic Oxidation of Hydroquinone,” The Journal of Physical Chemistry, vol. 95, No. 15, 1991, pp. 5970-5975. |
Hashiguchi, Yasuhiro, MD, et al., “Development of a Miniaturized Glucose Monitoring System by Combining a Needle-Type Glucose Sensor With Microdialysis Sampling Method,” Diabetes Care, vol. 17, No. 5, May 1994, pp. 387-389. |
Heller, Adam, “Electrical Wiring of Redox Enzymes,” Acc. Chem. Res., vol. 23, No. 5, May 1990, pp. 128-134. |
Jobst, Gerhard, et al., “Thin-Film Microbiosensors for Glucose-Lactate Monitoring,” Analytical Chemistry, vol. 68, No. 18, Sep. 15, 1996, pp. 3173-3179. |
Johnson, K.W., et al., “In vivo evaluation of an electroenzymatic glucose sensor implanted in subcutaneous tissue,” Biosensors & Bioelectronics, 7, 1992, pp. 709-714. |
Jönsson, G., et al., “An Electromechanical Sensor for Hydrogen Peroxide Based on Peroxidase Adsorbed on a Spectrographic Graphite Electrode,” Electroanalysis, 1989, pp. 465-468. |
Kanapieniene, J. J., et al., “Miniature Glucose Biosensor with Extended Lineality,” Sensors and Actuators, B. 10, 1992, pp. 37-40. |
Kawamori, Ryuzo, et al., “Perfect Normalization of Excessive Glucagon Responses to Intraveneous Arginine in Human Diabetes Mellitus With the Artificial Beta-Cell,” Diabetes vol. 29, Sep. 1980, pp. 762-765. |
Kimura, J., et al., “An Immobilized Enzyme Membrane Fabrication Method,” Biosensors 4, 1988, pp. 41-52. |
Koudelka, M., et al., “In-vivo Behaviour of Hypodermically Implanted Microfabricated Glucose Sensors,” Biosensors & Bioelectronics 6, 1991, pp. 31-36. |
Koudelka, M., et al., “Planar Amperometric Enzyme-Based Glucose Microelectrode,” Sensors & Actuators, 18, 1989, pp. 157-165. |
Mastrototaro, John J., et al., “An electroenzymatic glucose sensor fabricated on a flexible substrate,” Sensors & Actuators, B. 5, 1991, pp. 139-144. |
Mastrototaro, John J., et al., “An Electroenzymatic Sensor Capable of 72 Hour Continuous Monitoring of Subcutaneous Glucose,” 14th Annual International Diabetes Federation Congress, Washington D.C., Jun. 23-28, 1991. |
McKean, Brian D., et al., “A Telemetry-Instrumentation System for Chronically Implanted Glucose and Oxygen Sensors,” IEEE Transactions on Biomedical Engineering, Vo. 35, No. 7, Jul. 1988, pp. 526-532. |
Monroe, D., “Novel Implantable Glucose Sensors,” ACL, Dec. 1989, pp. 8-16. |
Morff, Robert J., et al., “Microfabrication of Reproducible, Economical, Electroenzymatic Glucose Sensors,” Annuaal International Conference of teh IEEE Engineering in Medicine and Biology Society, Vo. 12, No. 2, 1990, pp. 483-484. |
Moussy, Francis, et al., “Performance of Subcutaneously Implanted Needle-Type Glucose Sensors Employing a Novel Trilayer Coating,” Analytical Chemistry, vol. 65, No. 15, Aug. 1, 1993, pp. 2072-2077. |
Nakamoto, S., et al., “A Lift-Off Method for Patterning Enzyme-Immobilized Membranes in Multi-Biosensors,” Sensors and Actuators 13, 1988, pp. 165-172. |
Nishida, Kenro, et al., “Clinical applications of teh wearable artifical endocrine pancreas with the newly designed needle-type glucose sensor,” Elsevier Sciences B.V., 1994, pp. 353-358. |
Nishida, Kenro, et al., “Development of a ferrocene-mediated needle-type glucose sensor covereed with newly designd biocompatible membrane, 2-methacryloyloxyethylphosphorylcholine-co-n-butyl nethacrylate,” Medical Progress Through Technology, vol. 21, 1995, pp. 91-103. |
Poitout, V., et al., “A glucose monitoring system for on line estimation oin man of blood glucose concentration using a miniaturized glucose sensor implanted in the subcutaneous tissue adn a wearable control unit,” Diabetologia, vol. 36, 1991, pp. 658-663. |
Reach, G., “A Method for Evaluating in vivo the Functional Characteristics of Glucose Sensors,” Biosensors 2, 1986, pp. 211-220. |
Shaw, G. W., et al., “In vitro testing of a simply constructed, highly stable glucose sensor suitable for implantation in diabetic patients,” Biosensors & Bioelectronics 6, 1991, pp. 401-406. |
Shichiri, M., “A Needle-Type Glucose Sensor—A Valuable Tool Not Only For a Self-Blood Glucose Monitoring but for a Wearable Artifiical Pancreas,” Life Support Systems Proceedings, XI Annual Meeting ESAO, Alpbach-Innsbruck, Austria, Sep. 1984, pp. 7-9. |
Shichiri, Motoaki, et al., “An artificial endocrine pancreas—problems awaiting solution for long-term clinical applications of a glucose sensor,” Frontiers Med. Biol. Engng., 1991, vol. 3, No. 4, pp. 283-292. |
Shichiri, Motoaki, el al., “Closed-Loop Glycemic Control with a Wearable Artificial Endocrine Pancreas—Variations in Daily Insulin Requirements to Glycemic Response,” Diabetes, vol. 33, Dec. 1984, pp. 1200-1202. |
Shichiri, Motoaki, et al., “Glycaemic Control in a Pacreatectomized Dogs with a Wearable Artificial Endocrine Pancreas,” Diabetologia, vol. 24, 1983, pp. 179-184. |
Shichiri, M., et al., “In Vivo Characteristics of Neddle-Type Glucose Sensor—Measurements of Subcutaneous Glucose Concentrations in Human Volunteers,” Hormone and Metabolic Research, Supplement Series vol. No. 20, 1988, pp. 17-20. |
Shichiri, M., et al., “Membrane design for extending the long-life of an implantable glucose sensor,” Diab. Nutr. Metab., vol. 2, No. 4, 1989, pp. 309-313. |
Shichiri, Motoaki, et al., “Normalization of the Paradoxic Secretion of Glucagon in Diabetes Who Were Controlled by the Artificial Beta Cell,” Diabetes, vol. 28, Apr. 1979, pp. 272-275. |
Shichiri, Motoaki, et al., “Telemetry Glucose Monitoring Device with Needle-Type Glucose Sensor: A useful Tool for Blood Glucose Monitoring in Diabetic Individuals,” Diabetes Care, vol. 9, No. 3, May-Jun. 1986, pp. 298-301. |
Shichiri, Motoaki, et al., “Wearable Artificial Endocrine Pancreas with Needle-Type Glucose Sensor,” The Lancet, Nov. 20, 1982, pp. 1129-1131. |
Shichiri; Motoaki, et al., “The Wearable Artificial Endocrine Pancreas with a Needle-Type Glucose Sensor: Perfect Glycemic Control in Ambulatory Diabetes,” Acta Paediatr Jpn 1984, vol. 26, pp. 359-370. |
Shinkai, Seiji, “Molecular Recognitiion of Mono- and Di-saccharides by Phenylboronic Acids in Solvent Extraction and as a Monolayer,” J. Chem. Soc., Chem. Commun., 1991, pp. 1039-1041. |
Shults, Mark C., “A Telemetry-Instrumentation System for Monitoring Multiple Subcutaneously Implanted Glucose Sensors,” IEEE Transactions on Biomedical Engineering, vol. 41, No. 10, Oct. 1994, pp. 937-942. |
Sternberg, Robert, et al., “Study and Development of Multilayer Needle-type Enzyme-based Glucose Microsensors,” Biosensors, vol. 4, 1988, pp. 27-40. |
Tamiya, E., et al., “Micro Glucose Sensors using Electron Mediators Immobilized on a Polypyrrole-Modified Electrode,” Sensors and Actuators, vol. 18, 1989, pp. 297-307. |
Tsukagoshi, Kazuhiko, et al., “Specific Complexation with Mono- and Disaccharides that can be Detected by Circular Dichroism,” J. Org. Chem., vol. 56, 1991, pp. 4089-4091. |
Urban, G,, et al., “Miniaturized multi-enzyme biosensors integrated with pH sensors on flexible polymer carriers for in vivo applciations,” Biosensors & Bioelectronics, vol. 7, 1992, pp. 733-739. |
Ubran, G., et al., “Miniaturized thin-film biosensors using covalently immobilized glucose oxidase,” Biosensors & Bioelectronics, vol. 6, 1991, pp. 555-562. |
Velho, G., et al., “In vivo calibration of a subcutaneous glucose sensor for determination of subcutaneous glucose kinetics,” Diab. Nutr. Metab., vol. 3, 1988, pp. 227-233. |
Wang, Joseph, et al., “Needle-Type Dual Microsensor for the Simultaneous Monitoring of Glucose and Insulin,” Analytical Chemistry, vol. 73, 2001, pp. 844-847. |
Yamasaki, Yoshimitsu, et al., “Direct Measurement of Whole Blood Glucose by a Needle-Type Sensor,” Clinics Chimica Acta, vol. 93, 1989, pp. 93-98. |
Yokoyama, K., “Integrated Biosensor for Glucose and Galactose,” Analytica Chimica Acta, vol. 218, 1989, pp. 137-142. |
Number | Date | Country | |
---|---|---|---|
20180240236 A1 | Aug 2018 | US |